Aileron Therapeutics, Inc.:
Clinical stage oncology company conducting 3 clinical trials for its lead candidate, ALRN-6924, a first-in-class/best-in-class drug that targets the p53 pathway. ALRN-6924 is from the Stapled peptide platform and is the only clinical drug candidate that binds equipotently to both of the p53 suppressor proteins, MDMX and MDM2. This company has now initiated of a Phase 1 / 1b in Acute Myeloid Leukemia (AML) and a Phase 2a in Peripheral T-Cell Lymphoma.
Phase l or ll
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Stock Market Data
Market Data copyright © 2019 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by